Altimmune (NASDAQ: ALT)
Altimmune Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Altimmune Company Info
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
News & Analysis
Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.
Viking Therapeutics has garnered a lot of attention following a successful clinical trial for its obesity care drug. But another development-stage biotech may have a superior candidate.
Wall Street Absolutely Loved This Biotech Stock. But It Just Crashed More Than 50%.
It's not the end of the story for this once high-flying biotech stock.
Why Altimmune, Foghorn Therapeutics, and Precigen Shares Crashed This Week
Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week.
My 3 Top Biotech Stock Picks for 2023
Biotech stocks are set to shine in 2023.
Why Altimmune Stock Is Under Pressure Today
Safety concerns poured water on otherwise positive clinical trial results for the company's experimental weight-loss drug.
Why Altimmune Is Crashing Today
The company halts development on both a COVID-19 vaccine and a drug targeting the disease.
Here's Why Altimmune Stock Is Surging Today
An experimental new weight loss drug produced compelling data in an early stage clinical trial.
Is Altimmune a Buy?
If you're thinking of investing in this spectacular coronavirus growth stock, now may be too late.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.